MedTrace Logo

Perineural Dexmedetomidine for Ulnar Nerve Block.

NCT03222323 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-07-31

No results posted yet for this study

Summary

The aim of this trial is to investigate if dexmedetomidine prolongs the duration of an ulnar nerve block. By using healthy volunteers the investigators can perform bilateral ulnar nerve blocks and thereby control for a systemic effect to clarify if the effect is actually peripheral or systemic. The investigators hypothesis is that dexmedetomidine as an adjunct to a local anaesthetic prolongs the duration of a peripheral nerve block by a peripheral mechanism.

Conditions

  • Healthy

Interventions

DRUG

Dexmedetomidine perineurally

Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.

DRUG

Ropivacaine 5mg/ml

Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.

DRUG

Ropivacaine 7.5mg/ml

In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.

DRUG

Dexmedetomidine systemically

Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.

DRUG

Isotonic saline

placebo (saline) is administered perineurally in all but the perineural group.

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Jakob H Andersen, M.D. · Department of Anesthesiology, Zealand University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-17
Primary Completion
2018-01-01
Completion
2018-04-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03222323 on ClinicalTrials.gov